MedTrace Logo

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

NCT06412965 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 528

Last updated 2025-01-13

Study results available
· View outcomes & findings →

Summary

This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.

Conditions

  • Migraine Disorders

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2024-01-03
Completion
2024-01-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412965 on ClinicalTrials.gov